Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention -- Cycle 2 2023

Funding Agency:
Patient-Centered Outcomes Research Institute

The Patient-Centered Outcomes Research Institute (PCORI) plans to reissue a modified Targeted PCORI Funding Announcement on May 2, 2023 (Cycle 2 2023) seeking to fund rigorous, large-scale pragmatic trials that compare newly available pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine. For this funding announcement, applicants may request coverage of patient care costs (including medical products, procedures, and care services) for potential funding by PCORI. For additional information, please see the full announcement upon posting.

Preventive treatments include both pharmacological and nonpharmacological options, with the goal of reducing the frequency, severity, and duration of attacks. Although there are many pharmacological options used for migraine prevention, most options were originally developed for the treatment of other conditions. Newly approved treatments such as calcitonin gene-related peptide (CGRP) antagonists have been developed specifically for migraine prevention and have been shown to be efficacious. However, there are uncertainties regarding the long-term comparative effectiveness of CGRP inhibitors compared with commonly prescribed preventives. Further, there is growing interest in the use of nonpharmacological therapies and additional research is needed to understand the role of such options in the prevention of migraine.

Letter of Intent (LOI) Deadline: May 31, 2023




Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 31, 2023